NEWARK Calif. Sept. 20 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced preliminary results from the Phase 1 study of PTG300 in normal healthy volunteers. PTG300 is an injectable hepcidin mimetic peptide discovered using the compa...
↧